Real world experience has demonstrated patients supplementing semaglutide with targeted nutrition and resistance exercise maintain more lean mass, lose more visceral fat, and achieve superior long-term metabolic outcomes than drug or lifestyle alone
In the United States, efforts are underway to alleviate supply constraints, but manufacturing capacity remains a limiting factor
Metformin, GLP-1 receptor agonists like Ozempic (prescribed off-label for weight loss), and other agents may qualify if the patient meets specific clinical criteria
Similar to the dual GLP-1/GCGR agonists, a series of GLP-1/GIP/GCGR tri-agonists have made it to clinical development [117] and have shown favourable efficacy and safety in clinical studies [119, 120]
By following our expert-guided program, many individuals in Kansas City have witnessed remarkable improvements in their weight and overall quality of life